‰«“ꌧˆãŽt‰ï > ‰«“ꌧˆãŽt‰ï‚ÌŠˆ“® > ˆãŽt‰ï•ñ > 7ŒŽ†

‹´–{•a\bó‘B‹@”\’ቺÇ

—®‹…‘åŠwˆãŠw•”“à•ª”å‘ãŽÓ“à‰Èi‘æ“ñ“à‰Èj‹³Žö
ûü{@Ms

y—v@Ž|z

Ž©ŒÈ–Ɖu«bó‘BŽ¾Š³‚ɂ̓oƒZƒhƒE•a‚Æ‹´–{•a‚ª‚ ‚éB‹´–{•a‚Íbó‘B‹@”\’ቺ Ç‚ÌŒ´ˆö‚Å‚ ‚éB‹´–{•a‚Å‚ÍRbó‘Bƒyƒ‹ƒIƒLƒVƒ_[ƒ[R‘ÌiTPOAbj‚ ‚é‚¢‚ÍR ƒTƒCƒƒuƒƒuƒŠƒ“R‘ÌiTGAbj‚ª—z«‚É‚È‚éB‹´–{•a‚Ìf’f‚Í‘gDfBŽÀÛ‚É‚Í R‘ÌTPOAb ‚ ‚é‚¢‚ÍTGAb ‚ª—z«‚Å‚ ‚ê‚ÎA‹´–{•a‚Æf’fB‹´–{•a‚Ì‘gD‚ÆR‘Ì TPOAb ETGAb ’l‚ð”äŠr‚µ‚½BTPOAb ETGAb ‚Ì‹´–{•af’f‚ÌŠ´“xE“ÁˆÙ“x‚Í ‚‚­‚Í‚È‚©‚Á‚½BTPOAb ‚»‚µ‚ÄTGAb ‚Í‹´–{•a‚ÌŒ´ˆö‚Å‚Í‚È‚­A‹´–{•a‚Ì‚Æ‚«‚É oŒ»‚·‚éRbó‘BR‘Ì‚Å‚ ‚éB

TSH Žó—e‘ÌR‘ÌTRAb ‚É‚ÍŽhŒƒR‘ÌTSAb ‚ƃuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚ª‚ ‚éB ƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚Íbó‘B‹@”\’ቺǂ̌´ˆö‚Å‚ ‚éBŒoŽž“I‚ÉŽhŒƒR‘Ì TSAb ‚©‚çƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚ÉATSBAb ‚©‚çTSAb ‚É‚È‚é—Ⴊ‚ ‚éB

ŒŸ¸GŒŒ’†bó‘Bƒzƒ‹ƒ‚ƒ“iT4AT3A—V—£T4A—V—£T3j’á’lBTSH ‚’lB TPOAb ETGAb —z«B‚Æ‚«‚ÉTRAb iTSBAbj—z«B

f’fGbó‘BŽîA”畆Š£‘‡A™–¬A”S‰t…Žî—lŠç–eBŒŒ’†bó‘Bƒzƒ‹ƒ‚ƒ“’á’lB TSH ‚’lBTPOAb ETGAb —z«B‚Æ‚«‚ÉTRAb iTSBAbj—z«B

Ž¡—ÃGbó‘Bƒzƒ‹ƒ‚ƒ““Š—^BT4 “Š—^B

‡T. ‹´–{•a‚Ì’è‹`EŠT”O1-3j

bó‘B‹@”\’ቺǂ̌´ˆö‚Ì‘å•”•ª‚Í‹´–{•a‚Å ‚ ‚éB‹´–{•a‚ÍŽ©ŒÈ–Ɖu«–«bó‘B‰Ši–« bó‘B‰Šj‚Å‚ ‚éB

‹´–{ô‚Í4 —á‚Ì’†”N—«‚Ìd‚¢‚Ñ‚Ü‚ñ«bó ‘BŽî‚ð‘gDŠw“I‚ÉŒŸõ‚µA‚“xƒŠƒ“ƒp‹…ZA ‘@ˆÛ‘BA‚»‚µ‚Äàh–Eã”ç×–E•Ï«‚ð”F‚ßA“Æ —§Ž¾Š³‚Æ‚µ‚½1jB‹´–{•a‚ÍŽ©ŒÈ–ƉuŽ¾Š³‚Å‚ ‚éB bó‘Bàh–E×–E‚ª•Ï«EˆÞk‚µAbó‘B‹@”\’á ‰ºÇ‚É‚È‚éB1j‚“xƒŠƒ“ƒp‹…ZA2j‘@ˆÛ‘ BA‚»‚µ‚Ä3jàh–Eã”ç×–E•Ï«AˆÈã3 ‚‚ª‹´ –{•abó‘B‚Ì‘gDŠŒ©‚Å‚ ‚éB1j2j3j‚É‚Í’ö“x ‚Ì·‚ª‚ ‚éB—Õ°“I‚É‚à–³Çó‚©‚ç‚“xbó‘B ‹@”\’á‰ºÇ‚ðŽ¦‚·‚à‚Ì‚Ü‚Å‚ ‚éBbó‘BŽî‚Ì‚Ý ‚Åbó‘B‹@”\‚ͳí‚Å‚ ‚é—Ⴊ‘½‚¢B‚“xbó ‘B‹@”\’ቺNJ³ŽÒ‚Ìbó‘B‚ł̓Šƒ“ƒp‹…ZA ‘@ˆÛ‘BA‚»‚µ‚Äàh–Eã”ç×–E•Ï«‚ð‚Ý‚éBb ó‘Bàh–E×–E‹@”\‚ª‚È‚¢Bbó‘B‹@”\’á‰ºÇ‚É ‚È‚éB

‹´–{•a‚ÍŽ©ŒÈ–ƉuŽ¾Š³‚Å‚ ‚èAbó‘BR‘Ì‚ª —z«‚É‚È‚éBbó‘BR‘Ì‚É‚Íbó‘Bƒyƒ‹ƒIƒLƒV ƒ_[ƒ[R‘ÌiTPOAbjAƒTƒCƒƒOƒƒuƒŠƒ“R‘Ì iTGAbj‚ª‚ ‚éB‹´–{•a‚ÌŠm’è‚Í‘gDf’f‚Å ‚ ‚éBŽÀÛ‚É‚ÍTPOAb ‚ ‚é‚¢‚ÍTGAb ‚ª—z« ‚Å‚ ‚ê‚ÎA‹´–{•a‚Æf’f‚µ‚Ä‚¢‚éBTPOAb ‚  ‚é‚¢‚ÍTGAb —z«ŽÒ‚Ì1 Š„‚ªbó‘B‹@”\’á‰ºÇ ‚É‚È‚é4jB

Rbó‘BR‘Ì‚É‚ÍTPOAbATGAb ‚Ì‘¼‚É TSH Žó—e‘ÌR‘ÌiTRAbj‚ª‚ ‚éBTRAb ‚É ‚Íbó‘BŽhŒƒR‘ÌTSAbithyroid stimulating antibodyj‚ƃuƒƒbƒLƒ“ƒOR‘ÌTSBAb iTSH-stimulation blocking antibodyj‚ª‚ ‚éBŽhŒƒR‘ÌTSAb ‚̓oƒZƒhƒE•a‚ÌŒ´ˆö‚É‚È ‚éBƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚Íbó‘B‹@”\’á ‰ºÇ‚ÌŒ´ˆö‚É‚È‚éBbó‘B‹@”\’ቺǂ̌´ˆö‚É ‚ÍTSBAb ‚ª‚ ‚éB

Ž©ŒÈ–Ɖu«–«bó‘B‰Š[ a u t o i m m u n e chronic thyroiditis] [‹´–{•aiL‹`j]‚É‚Íb ó‘BŽî‚Ì‚ ‚é‚à‚Ì‚Æ‚È‚¢‚à‚Ì‚ª‚ ‚éB‘OŽÒbó ‘BŽî‚Ì‚ ‚é‚à‚Ì‚ð‹´–{•ai‹·‹`j[autoimmune goitrous iHashimoto'sj thyroiditis]‚Æ‚¢‚¢A ŒãŽÒbó‘BŽî‚Ì‚È‚¢‚à‚Ì‚ðˆÞk«bó‘B‰Š [autoimmune atrophic thyroiditis]‚Æ‚¢‚¤5jB ‚±‚̈Þk«bó‘B‰Š‚ł̓uƒƒbƒLƒ“ƒOR‘Ì TSBAb ‚ª—z«‚É‚È‚éBTSBAb ‚ÍTSH Žó—e‘Ì R‘ÌTRAb ‚Å‚ ‚éB

‹´–{•a‚Å‚ÍŽ©ŒÈ–Ɖu‚É‚æ‚èbó‘B‘gD”j‰ó‚ª ¶‚¶Abó‘Bƒzƒ‹ƒ‚ƒ“‚ªŒŒ’†‚É—¬o‚·‚邱‚Æ‚ª ‚ ‚éBbó‘B’†“ÅÇ‚ðŽ¦‚·B‚±‚ê‚ð”j‰ó«bó ‘B‰Š‚Æ‚¢‚¤B‚₪‚Ä‹@”\’ቺǂɂȂéB

‡U. •aˆöA‹´–{•a”­Ç‹@\2,3j

ˆâ“`“I‘fˆö‚ªd—v‚È–ðŠ„‚ð‰Ê‚½‚·B‘fˆö‚Ì‚  ‚él‚ÉŽ©ŒÈ–ƉuˆÙ킪‚¨‚±‚èA‹´–{•a‚É‚È‚éB —Uˆö‚ª‚ ‚éB

1D‹´–{•a”­Ç‚̈â“`”wŒi

‹´–{•a‚͉Ƒ°“à‚Å”­Ç‚·‚éBˆâ“`“I”wŒi‚ª‚  ‚éB‹´–{•a‚Í‘¼‚ÌŽ©ŒÈ–Ɖu«“à•ª”厾Š³‚Ƈ•¹ ‚·‚éBIDDMA‹´–{•aAƒoƒZƒhƒE•aAAddison iƒAƒfƒBƒ\ƒ“j•a‚È‚Ç‚ÌŽ©ŒÈ–ƉuŽ¾Š³‚͇•¹‚· ‚éB‚ ‚éŽí‚̈â“`”wŒi‚ðŽ‚Š³ŽÒ‚Í‹´–{•a‚Éœë ‚è‚â‚·‚¢BHLAACTLA-4 ‚̈â“`Žq‘½Œ^‚ªŠÖ ŒW‚·‚éB

2DŽ©ŒÈ–ƉuˆÙí

1j‘̉t«–ƉuFbó‘BŽ©ŒÈR‘Ìithyroid autoantibodyj

@bó‘BR‘Ì‚É‚ÍT P O A b AT G A b A TRAb ‚ª‚ ‚éBˆÞk«bó‘B‰Š‚ł̓uƒƒb ƒLƒ“ƒOR‘ÌT S B A b ‚ª—z«‚É‚È‚éB TSBAb ‚Íbó‘B‹@”\’ቺǂ̌´ˆö‚Å‚  ‚éBTSBAb ‚ÍTRAb ‚Å‚ ‚éBTSAb ‚̓o ƒZƒhƒE•a‚ÌŒ´ˆö‚Å‚ ‚éBTSBAb ‚àTSAb ‚àTRAb ‚Å‚ ‚éB

2j×–E«–Ɖuicell-mediated immunityj

@×–E«–Ɖu‚ÍR‘Ì‚ªŠÖ—^‚µ‚È‚¢‚ÅA×–E ‚ª’¼Úì—p‚·‚é–Ɖu”½‰ž‚Å‚ ‚éBbó‘B‚É ‘΂·‚é×–E«–Ɖu‚ª‚ ‚éBbó‘B‚ɂ̓Šƒ“ ƒp‹…‚ÌZ‚ª‚ ‚èA‚±‚̃Šƒ“ƒp‹…‚Íbó‘B ×–E‚É’¼Úì—p‚·‚éB

3jR‘̈ˑ¶«×–E«×–EŠQiantibodydependent cellular cytotoxicity F ADCCj

@‰t«R‘Ì‚Æ×–E«–Ɖu‚Ì‹¦“¯ì—p‚Æ‚µ‚Ä ADCC ‚ª‚ ‚éBADCC ‚Í‹´–{•a‚Å‚à‚Ý‚ç ‚ê‚éB–Ɖu×–E‚ÍR‘̂𒇉î‚Æ‚µA•W“I× –E‚É•t’…‚µA×–E‚ÉŠQ‚ð—^‚¦‚éB‚±‚Ì‚æ ‚¤‚Èì—p‚ðŽ¦‚·–Ɖu×–E‚ÍK ×–EiƒLƒ‰[ T ×–Ej‚Å‚ ‚éBR‘ÌŽ©g‚Íbó‘B×–E‚ð ŠQ‚µ‚È‚¢BR‘Ì‚Í×–E•\–Ê‚ÉŒ‹‡‚µA–Æ ‰u•¡‡‘Ì‚ª‚Å‚«‚éB‚±‚̖Ɖu•¡‡‘Ì‚ÌR‘Ì Fc •”•ª‚ÉK ×–E‚ªŒ‹‡‚µAbó‘B×–E“à ‚É“ü‚Á‚Ä×–E‚ð”j‰ó‚·‚éBADCC ‚͈Þk «bó‘B‰ŠA‹´–{•a‚Å‚Ý‚ç‚ê‚éB

‹´–{•aAƒoƒZƒhƒE•a”­Ç‚ɂ̓wƒ‹ƒp[T ×–E iTH ×–Ej‚ªd—v‚È–ðŠ„‚ð‰Ê‚½‚·B‹´–{•a‚Å ‚ÍTH1 —DˆÊAƒoƒZƒhƒE•a‚Å‚ÍTH2 —DˆÊ‚Å‚ ‚éB ‹´–{•a‚Å‚Í×–EáŠQ”½‰žAƒoƒZƒhƒE•a‚Å‚ÍR‘Ì TRAbiTSAbjŽY¶‚ªŽå‘Ì‚É‚È‚éB‚µ‚©‚µA ƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb —z«ˆÞk«bó‘B‰Š ‚Å‚ÍTH2 —DˆÊ‚Å‚ ‚éBR‘ÌTRAbiTSBAbj ŽY¶iTH2j‚ªŽå‘̂ɂȂ邪A×–EáŠQiTH1j ‚à‚Ý‚ç‚ê‚éB

3D‹´–{•a”­ÇE‘ˆ«‚̊‹«ˆöŽq2,3j

ƒˆ[ƒh‚Í‹´–{•a‚Ì”­ÇA‘ˆ«‚ÉŠÖŒW‚·‚éBƒˆ [ƒhŒ‡–R’nˆæ‚Å‚Í­—ʃˆ[ƒh“Š—^‚ª‹´–{•a‚Ì”­ Ç•p“x‚ð—}‚¦‚éBˆê•ûA‘å—ʃˆ[ƒh‚Í‹´–{•a‚Ì ”­Ç‚⑈«‚ÉŠÖ—^‚·‚éBAmiodarone ‚̓ˆ[ƒh‚ð ŠÜ—L‚µ‚Ä‚¨‚èAbó‘BŽ©ŒÈ–ƉuŽ¾Š³‚ð—U”­‚·‚éB

ƒoƒZƒhƒE•aŠ³ŽÒ‚ðI131 •úŽËü‚ÅŽ¡—·‚é‚ÆA ƒuƒƒbƒLƒ“ƒOR‘ÌiTSBAbj‚ªoŒ»‚µAbó ‘B‹@”\’ቺǂɂȂé—Ⴊ‚ ‚éBI131 •úŽËüŽ¡—à ŒãTRAb ‚ª‚’l‚É‚È‚é—Ⴊ‚ ‚éB‚±‚ê‚ÍI131 ‚Å bó‘B‚ª”j‰ó‚³‚êAŒŒ’†‚Ébó‘B‘gD‚ª—¬o ‚µA‚»‚Ì—¬o‚µ‚½bó‘B‘gD‚ªRŒ´‚Æ‚È‚Á‚ÄR‘Ì‚ðì‚éBI131 •úŽËü—Ö@‚ªŽ©ŒÈ–Ɖu«bó‘B ‰Š‚ðˆø‚«‹N‚±‚·B‚Ü‚½ˆŸ‹}«bó‘B‰Š‚ÌŒã‚É TSBAb ‚ªo‚Ä‚«‚Ä‹@”\’ቺǂɂȂé—Ⴊ‚ ‚éB

ƒCƒ“ƒ^[ƒtƒFƒƒ“Ž¡—Âɂæ‚èA–«bó‘B‰Š ‚ª‘ˆ«‚ ‚é‚¢‚Í”­Ç‚·‚éB

”DPEoŽY‚ÉŠÖ˜A‚µ‚½Ž©ŒÈ–Ɖu«bó‘B‹@”\ ˆÙíÇ‚ª‚ ‚éBCushingiƒNƒbƒVƒ“ƒOjpŒã‚  ‚é‚¢‚Í•›t”玿ƒzƒ‹ƒ‚ƒ““Š—^’†Ž~Œãbó‘B‹@”\ ˆÙíÇ‚ª‹N‚±‚éBu‰ßè•›t”玿ƒzƒ‹ƒ‚ƒ“‚ª‹}Œƒ ‚ɒቺ‚µ‚½‚Æ‚«‚Ébó‘B‹@”\ˆÙíÇ‚ªo‚Ä‚­‚év ‚Æ‚¢‚¤‚±‚Æ‚ÍoŽYŒã‚Ìbó‘B‹@”\ˆÙíÇ‚Ì”­Ç ‹@˜‚ðà–¾‚·‚éBƒXƒeƒƒCƒh‚Ì‹}Œƒ‚ȕω»‚ªŽ© ŒÈ–ƉuˆÙíAbó‘B‹@”\ˆÙí‚ðˆø‚«‹N‚±‚·B

Human T-lymphotrophic virus type I iHTLV-IjŠ´õŽÒ‚Å‚ÍŽ©ŒÈ–ƉuŽ¾Š³‚ª‘½‚¢B ‹´–{•a‚Ì•p“x‚à‘½‚¢4jBƒ`ƒGƒ‹ƒmƒuƒCƒŠ•úŽËü Ž–ŒÌ‚Å–«bó‘B‰Š‚ª‘‰Á‚µ‚½B

‡V. ‰uŠw2j

—«‚É‘½‚¢B’j«1 ‚ɑ΂µ—«2 ` 7 ‚Å‚ ‚éB 30 ` 60 Αä‚É‘½‚¢BRbó‘BR‘Ì‚ª—z«‚É‚È ‚é‚̂ͬl—«‚Ì10 ` 20 “‚Å‚ ‚éBbó‘BR ‘Ì—z«ŽÒ‚Ì10 “‚ªbó‘B‹@”\’ቺǂɂȂé4jB ¬l‚Ì‹´–{•a‚É‚æ‚ébó‘B‹@”\’ቺǂ̕p“x‚Í ‚Ù‚ÚƒoƒZƒhƒE•a‚Ì•p“x‚Æ“¯‚¶‚Å‚ ‚éB

‡W. •a—

bó‘B‚Í‚Ñ‚Ü‚ñ«‚ÉŽî‘債A•\–Ê‚Í‘e‘åè÷—± ó‚Åd‚¢B‘gDŠw“I‚É‚Í1j‚“xƒŠƒ“ƒp‹…ZA ƒŠƒ“ƒpàh–EEãó’†S‚ÌŒ`¬A2jŠÔŽ¿‘@ˆÛ‰»A‘@ ˆÛ‘BA‚»‚µ‚Ä3jàh–Eã”ç×–E•Ï«AˆÈã3 ‚ ‚ª‹´–{•abó‘B‚Ì“Á’¥‚Å‚ ‚é1jB•a•Ï‚ªbó‘B ‘S‘Ì‚É‹y‚ñ‚Å‚¢‚é‚à‚Ìi‚Ñ‚Ü‚ñ«bó‘B‰Šdiffuse thyroiditisjA•a•Ï‚ªŽUÝ‚·‚é‚à‚ÌiŽUÝ «bó‘B‰Šfocal thyroiditisjA‚»‚µ‚ăŠƒ“ƒp ‹…Z‚ðŽUÝ«‚É”F‚߂邾‚¯‚Ì‚à‚Ì‚à‚ ‚éB

‡X. ‹´–{•abó‘B‹@”\’ቺǂ̗հÇó6j

bó‘BŽî‚ª‚ ‚éBbó‘BŽî‚Í‚Ñ‚Ü‚ñ«‚ÅAÅ ‰‚Í_‚ç‚©‚¢‚ªA‚₪‚Äd‚­‚È‚éB•\–Ê‚Í•s ®BŽ©”­’ÉAˆ³’É‚Í‚È‚¢BŒz•”ˆá˜aŠ´E•s‰õŠ´‚ð‘i‚¦‚éBbó‘B‹@”\‚͉‚߂ͳí‚Å‚ ‚邪A ‚₪‚Äbó‘B‘gD‚ª”j‰ó‚³‚êAbó‘B‹@”\’ቺ Ç‚É‚È‚éB‰Šú‚Å‚Íbó‘BŽî‚Ì‚Ý‚ð”F‚ß‚éB

bó‘B‹@”\’ቺǂɂȂéBbó‘B‹@”\’á‰ºÇ ‚Í“Á—L‚ÌŠç–eAºA˜b‚µ•û‚©‚çf’f‚·‚éB‚Ü‚½ ‚»‚Ì“Á’¥“I‚Ⱥ‚©‚ç“d˜b‚Å‚àf’f‚Å‚«‚éB‰Šú ‚ÌÇó‚Í”ñ“ÁˆÙ“I‚ÅA‘½Ê‚Å‚ ‚éBbó‘Bƒzƒ‹ ƒ‚ƒ“Œ‡–R‚É‚æ‚èA‘ãŽÓ‚ª’ቺ‚µAƒ€ƒR‘½“œ—Þ‚ª ’¾’…‚µA”S‰t…Žî‚ª‚Ý‚ç‚ê‚éB—Õ°Çó‚Í2 ‚ ‚É•ª‚¯‚邱‚Æ‚ª‚Å‚«‚éi•\1jB1jbó‘Bƒzƒ‹ƒ‚ ƒ“Œ‡–R‚É‚æ‚éV’‘ãŽÓ’ቺ‚ÌÇó‚Æ2j”S‰t…Žî «Z‚É‚æ‚éÇó‚Å‚ ‚éB”S‰t…Žî«Z‚̓q ƒAƒ‹ƒƒ“Ž_‚âƒRƒ“ƒhƒƒCƒ`ƒ“—°Ž_‚É•x‚Þƒ€ƒR’` ”’‚Ì‘gDŠÔŒ„‚Ö‚Ì’¾’…‚É‚æ‚é•‚Žî‚Å‚ ‚èAˆ³­ ‚ðŽc‚³‚È‚¢non-pitting edema ‚Å‚ ‚éB

•a—ðA–âf‚Å“¾‚ç‚ê‚éd—v‚ÈŠŒ©‚ͺ‚̕ω» ‚Å‚ ‚éBbó‘Bƒzƒ‹ƒ‚ƒ“‚ªŒ‡–R‚·‚é‚ƺ‘Ñ‚É•‚ Žî‚ª¶‚¶šm‚꺂ɂȂéBã‚̉^“®‚ªˆ«‚­A‰ï˜b ‚ª‚Ì‚ë‚­‚È‚èA“ï’®‚ං¶‚éB‰ï˜b‚ª“‚­‚È ‚éBu–°‚¢vAuŠ¦‚³‚ÉŽã‚¢vAu‹L‰¯—͒ቺvA u•Ö”év‚È‚Ç‚ð•·‚«o‚·B‚±‚ê‚ç‚Íbó‘Bƒzƒ‹ƒ‚ƒ“Œ‡–R‚ª’·ŠúŠÔ‘±‚¢‚½‚±‚Æ‚ðŽ¦‚·BäC• ‹Ø‚Ì áz¹i‚±‚Þ‚ç•Ô‚èj‚Í‘Šú‚ÉoŒ»‚·‚éB

Ž‹f‚Å‚ÍA”畆‚ªbó‘Bƒzƒ‹ƒ‚ƒ“Œ‡–R‚É•qŠ´ ‚É”½‰ž‚·‚éBŒ‡–R‚·‚é‚ÆA”畆‚ÍŠ£‘‡‚µA‘e ‚É‚È‚éB”畆‚Åbó‘B‹@”\’ቺǂð‹^‚¤B”S‰t …Žî—lŠç–e‚Í“Á’¥“IB“ª”¯‚Ì’E–ÑA”û–ÑŠO‘¤ 1/3 ‚Ì’E—ŽA–³‹C—Í—lŠç–e‚ªŒ©‚ç‚ê‚éBbó‘B Žî‚ª‚ ‚éB”畆‚ÌF‘f’¾’…‚ÍSchmidtiƒVƒ…ƒ~ ƒbƒgjÇŒóŒQ‚ðŽ¦´‚·‚éBSchmidt ÇŒóŒQ‚Í‹´ –{•a‚ÆAddison •a‚̇•¹B

Ž©ŠoÇó‚Æ‚µ‚Ä‚ÍA•‚Žîi•‚ŽîŠ´jAŠ¦‚ª‚èA ˆÕ”æ˜JŠ´Ašm‚êºAŒ¾—t‚Ì‚à‚‚êA“®ìŠÉ–A ¸_“Ý–ƒA–°‚ª‚èA“ï’®A”畆Š£‘‡i”§r‚êjA ’E–ÑA‘Ìd‘‰ÁAŒŽŒo‰ß‘½‚È‚Ç‚ª‚éB‘¼Šo“I‚É ‚ÍA”S‰t…Žî—lŠç–eAŒûO‚âã‚ÍŒú‚­i‹‘å ãjA’E–Ñ‚ª‚ ‚èA”û–Ñ‚àŠO‘¤1/3 ‚ª”–‚¢B”ç •†‚ÍŠ£‘‡‚µA‘e?‚Å‚ ‚èA‰©FiƒJƒƒ`ƒ“ŒŒ Çj‚É‚È‚éBŽè‘«‚É•‚Žî‚ª‚ ‚èAˆ³­‚ðŽc‚³‚È ‚¢Bº‚Í’á‚­Ašm‚꺂ɂȂéBŒ¾ŒêA“®ì‚ÍŠÉ –‚Å‚ ‚éBbó‘BŽî‚ª‚ ‚ê‚Îf’f‚Í—eˆÕ‚Å‚ ‚é ‚ªAbó‘BŽî‚Ì‚È‚¢‚à‚Ì‚à‚ ‚éBS‘Ÿ‚ÍŠg‘債A S‰¹‚Í”÷ŽãA™–¬‚É‚È‚éBŽž‚É‚Í‹¹…‚â• …‚ð ‚Ý‚éBƒAƒLƒŒƒXäF”½ŽË‚Ì’oŠÉ‘Š‰„’·‚Íf’f“I‰¿ ’l‚ª‚ ‚éB

•\1

•\1
‡Y. ŒŸ¸3,6j

bó‘BŽ©ŒÈR‘ÌiTPOAbATGAbj‚ª—z« ‚É‚È‚éBbó‘B‹@”\‚ÍŒŒ’†bó‘Bƒzƒ‹ƒ‚ƒ“iT 3AT4A—V—£T3A—V—£T4j‚ÆŒŒ’†TSH ‚Å‚Ý ‚éBTSH ‚̊l‚Í0.4 ` 4.0 ƒÊ U/mlimU/lj ‚Å‚ ‚éB‹´–{•a‚Íbó‘B«‚Ìbó‘B‹@”\’á‰ºÇ ‚Å‚ ‚èATSH ‚ª‚’l‚Æ‚È‚éBTSH 10 ƒÊ U/ml ˆÈã‚ÌŠ³ŽÒ‚Í‹´–{•a‚Ì10 “‚Å‚ ‚éB‹´–{•a‚Å ‚Íbó‘B‘gD‚ª”j‰ó‚³‚êAbó‘Bƒzƒ‹ƒ‚ƒ“‚ªŒŒ ’†‚ɘRo‚·‚邽‚ßAˆê‰ß«‚Ébó‘B’†“ÅÇ‚É‚È ‚éB‚»‚ÌŽžAŒŒ’†TSH ‚Í’á’l‚ðŽ¦‚·B

ˆê”ÊŒŸ¸‚Å‚ÍAŒŒ’¾‚ª˜´i‚µAƒÁ-ƒOƒƒuƒŠ ƒ“‚ª‘‰Á‚·‚éBCPK ‚âLDH ‚ª‘‰Á‚·‚éBŒŒ’† chol ‚Í‚’lB‹¹•”X üŽÊ^‚ÅSŠg‘åAS“d} ‚Å‚Í™–¬A’á“dˆÊAT ‚Ì•½’áE‰A«‰»‚ª‚Ý‚ç‚ê ‚éBbó‘B’´‰¹”g‚Å‚Íbó‘BŽî‘å‚Æ‘e?‰»‚ð ‚Ý‚éBŒŒ’†ƒvƒƒ‰ƒNƒ`ƒ“‚ª‚’l‚É‚È‚éB‰º‚‘Ì ‚ª‘å‚«‚­‚È‚éB

‡Z. ‹´–{•abó‘B‹@”\’ቺǂÌf’f2,3,6j

bó‘BŽ©ŒÈR‘ÌiTPOAbATGAbj‚Í—z«‚É ‚È‚éBbó‘BŽî‚ª‚ ‚èAbó‘BR‘Ì‚ª—z«‚Å‚  ‚é‚Æ‚«‹´–{•a‚ðl‚¦‚éBTRAb ‚ª—z«‚ɂȂ邱 ‚Æ‚ª‚ ‚éB‚±‚ÌTRAb ‚ÍTSBAb ‚Å‚ ‚éBbó ‘B‹@”\’ቺǂÌf’f‚Íbó‘B‹@”\ŒŸ¸‚É‚æ‚éB ŒŒ’†bó‘Bƒzƒ‹ƒ‚ƒ“‚Í’á’l‚ðŽ¦‚·B‹´–{•a‚Ì‚æ ‚¤‚Èbó‘B«bó‘B‹@”\’ቺǂłÍATSH ‚ª‚ ’l‚Æ‚È‚éBTSH ‚̊l‚Í0.4 ` 4.0 ƒÊ U/ml ‚Å ‚ ‚éB—Õ°Çó‚ªo‚Ä‚¢‚È‚¢—á‚Å‚àATSH ‚Í‚ ’l‚Æ‚È‚èA‘Šúf’f‚ɖ𗧂ÂB—V—£T3A—V—£ T4 ‚ª³í‚ÅATSH ‚ª4.0 ` 10 ƒÊ U/ml ‚Ì‚à‚Ì ‚ðöÝ«bó‘B‹@”\’ቺǂƂ¢‚¤B

‡[. bó‘B‹@”\’ቺǂ̎¡—Ã6j

bó‘Bƒzƒ‹ƒ‚ƒ“‚ð“Š—^‚·‚éB•â[—Ö@‚Å‚  ‚éBT4 ‚Å•â[‚·‚éBTSH 10 ƒÊ U/ml ˆÈã‚Ì Š³ŽÒ‚ÍT4 ‚ð•â[‚·‚éBT4 “Š—^‚Í‚—îŽÒ‚Å‚Í S‹Ø[ÇA‹·SÇ‚ð—U”­‚·‚éB‰º‚‘Ì«bó ‘B‹@”\’ቺǂł͂Ƃ«‚ɉº‚‘Ì«•›t”玿‹@ ”\’á‰ºÇ‚ð‡•¹‚·‚éB‚±‚̂悤‚È—á‚ÅT4 ‚ð“Š —^‚·‚é‚Æ•›t•s‘S‚ðˆø‚«‹N‚±‚·BT4 “Š—^‘O‚É •›t”玿ƒzƒ‹ƒ‚ƒ“‚ð“Š—^‚·‚éBSchmidt ÇŒóŒQ ‚Å‚à“¯‚¶‚悤‚ÉT4 “Š—^‘O‚É•›t”玿ƒzƒ‹ƒ‚ƒ“ ‚ð“Š—^‚·‚éBT4 •â[‚ÅTSH ‚ð³í‚ɕۂ‚悤 ‚É‚·‚éB

‡\. –ð‚É—§‚Â’mŽ¯

1jbó‘B‹@”\’ቺÇ6j

bó‘B‹@”\’ቺǂ͇T. bó‘B«iŒ´”­«jA ‡U. Ž‹°‰º•”«A‰º‚‘Ì«i“ñŽŸ«jA‡V.––½ «bó‘B‹@”\’ቺǂÌ3 ‚‚ɕª—Þ‚·‚éi•\2jB ‡V‚Íbó‘Bƒzƒ‹ƒ‚ƒ“•s‰žÇ‚Å‚ ‚éB‡T‚Ìbó‘B «iŒ´”­«jbó‘B‹@”\’ቺǂɂ͂¢‚ë‚¢‚ë‚  ‚邪AŽ©ŒÈ–Ɖu‚É‚æ‚é–«bó‘B‰Š‚ª‘½‚¢BŒŒ ’†bó‘Bƒzƒ‹ƒ‚ƒ“‚Ɖº‚‘ÌTSH •ª”å‚Æ‚ÌŠÔ‚É ‚Ínegative feedback ‚ª‚ ‚èAbó‘B«bó‘B ‹@”\’ቺǂł͌Œ’†TSH ‚ª‘‰Á‚·‚éB

–«bó‘B‰Š‚É‚Íbó‘BŽî‚Ì‚ ‚é–«bó‘B ‰Ši‹´–{•aj‚Æbó‘B‚ðG‚ê‚È‚¢ˆÞk«bó‘B ‰Š‚Æ‚ª‚ ‚éBˆÞk«bó‘B‰Š‚ł̓uƒƒbƒLƒ“ƒO R‘ÌTSBAb ‚ª—z«‚É‚È‚éBTSBAb ‚ÍTRAb ‚Å‚ ‚éBƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚Íbó‘B‹@ ”\‚ð—}§‚µAbó‘B‹@”\’ቺǂ̌´ˆö‚É‚È‚é5jB TSBAb ‚ÍTSH ‚Ìì—p‚ðƒuƒƒbƒN‚µAbó‘B ‹@”\‚ð—}§‚·‚éB

•\2

•\2
}1

}1D‹´–{•ai‘gD‚Åf’fj‚ÆR‘ÌTGAb A ‚ÆTPOAb B ‚ÌROC ‰ðÍ2j

2jTPOAbATGAbATSBAb ‚Æbó‘B‹@”\’á ‰ºÇ

‹´–{•a‚Ìf’f‚Í‘gDf‚Å‚ ‚邪A‘S‚Ä‚ÌÇ—á ‚Å‘gD‚ð‚݂邱‚Æ‚Í‚Å‚«‚È‚¢B]‚Á‚ÄTPOAbA TGAb ‚ª—z«‚ÅAbó‘B‹@”\’ቺǂª‚ ‚é‚Æ ‚«A‹´–{•a‚É‚æ‚ébó‘B‹@”\’ቺǂðl‚¦‚éB

T P O A bAT G A b ‚̓oƒZƒhƒE•a‚ÌT R A b iTBII ETSAbj‚Ù‚ÇŠ´“xE“ÁˆÙ“x‚ª—Ç‚­‚Í‚È ‚¢i}1j2jB‹´–{•a‚Å‚Íbó ‘Bàh–E‚ª”j‰ó‚³‚êAŒŒ’†‚Ébó ‘Bƒyƒ‹ƒIƒLƒVƒ_[ƒ[iTPOj ‚ƃTƒCƒƒOƒƒuƒŠƒ“iTGj‚ª —¬o‚µ‚ÄRŒ´‚Æ‚È‚èAR‘Ì TPOAb ‚ÆTGAb ‚ª‚Å‚«‚éBb ó‘B‹@”\’ቺǂ͋´–{•a‚É‚æ ‚èbó‘B‚ª”j‰ó‚³‚ꂽŒ‹‰Ê‚Å‚  ‚éBTPOAbATGAb ’l‚ÆAb ó‘B‹@”\’ቺǂ̒ö“x‚ª‘ŠŠÖ ‚·‚é‚Æ‚ÍŒÀ‚ç‚È‚¢BTPOAb ‚Æ TGAb ‚Íbó‘B‹@”\’á‰ºÇ‚Ì Œ´ˆö‚Å‚Í‚È‚¢B

TPOAbATGAb ‚Íbó‘B‹@ ”\’ቺǂ̌´ˆö‚Å‚Í‚È‚¢B‚»‚Ì ——R‚Í1jTPOAb ETGAb ‚Æ ‚à‘ª’芴“xˆÈ‰º‚Å‚ ‚é‚É‚à‚©‚© ‚í‚炸A‹´–{•a‚Ì‘gD•Ï‰»‚Æb ó‘B‹@”\’á‰ºÇ‚ðŽ¦‚·Ç—Ⴊ‚  ‚éB‚±‚Ì‚±‚Æ‚ÍTPOAb E TGAb ‚Í‹´–{•aEbó‘B‹@”\ ’ቺǂ̕aˆö‚Å‚È‚¢‚±‚Æ‚ðŽ¦´ ‚µ‚Ä‚¢‚éB2jTPOAb ETGAb ‚Í‹´–{•a‚Å—z«‚ɂȂ邪A TPOAb ETGAb ‚Íbó‘B‹@”\ ‚ð—}§‚·‚é‚킯‚Å‚Í‚È‚¢B

TPOAb ETGAb ‚Í‹´–{•a‚Ì Žw•W‚É‚·‚¬‚È‚¢B

ƒuƒƒbƒLƒ“ƒOR‘ÌTABAb ‚Í bó‘B‹@”\’ቺǂ̌´ˆö‚Å‚  ‚é5,7,8,16jB‚»‚Ì——R‚͇@ƒuƒƒb ƒLƒ“ƒOR‘ÌTSBAb ‚Íbó‘B‹@ ”\’ቺǂðˆø‚«‹N‚±‚·5,7,8,16jB TSBAb ‚͈Þk«bó‘B‰Š‚ÌŒ´ ˆö‚É‚È‚éBTSBAb ‚Íbó‘B‚ð ˆÞk‚³‚¹‚éB2j TSBAb ’l‚Æ—Õ °Œo‰ß‚ªˆê’v‚·‚é8jBTSBAb ‚ª ÁŽ¸‚·‚é‚Æbó‘B‹@”\’ቺǂ© ‚ç‰ñ•œ‚·‚é8jB3j TSBAb ‚ÍV¶ Ž™ˆê‰ß«bó‘B‹@”\’ቺǂ̌´ ˆö‚É‚È‚é7jBTSBAb ‹­—z«‚Ì•ê e‚ÌTSBAb ‚Í‘Ù”Õ‚ð’ʉ߂µA Ž™‚ɈÚs‚·‚éB‚±‚ÌTSBAb ‚ª Ž™‚Ìbó‘B‚ð—}§Abó‘B‹@”\ ’ቺǂðˆø‚«‹N‚±‚·B

TABAb ‚Íbó‘B‹@”\’á‰ºÇ ‚ÌŒ´ˆö‚Å‚ ‚éB

3jbó‘B‹@”\’ቺǂ©‚ç‰ñ•œ ‚·‚é‚à‚Ì9j

¬l‚Ìbó‘B‹@”\’á‰ºÇ‚Ì‘å •”•ª‚Í–«bó‘B‰Š‚É‚æ‚éB– «bó‘B‰Š‚É‚æ‚é‹@”\’á‰ºÇ‚Í ‰i‘±‚·‚é‚à‚Ì‚Æl‚¦‚ç‚ê‚Ä‚« ‚½B‘å•”•ª‚Íbó‘Bƒzƒ‹ƒ‚ƒ“•ž —p‚𒆎~‚Å‚«‚È‚¢bó‘B‹@”\’á ‰ºÇ‚Å‚ ‚éB‚µ‚©‚µ’†‚É‚Íbó ‘Bƒzƒ‹ƒ‚ƒ“•ž—p‚𒆎~‚Å‚«‚銳 ŽÒ‚ª‚¢‚é10jB’†Ž~‚Å‚«‚é‚à‚Ì i‰Â‹t«bó‘B‹@”\’ቺÇj‚É ‚ÍŽŸ‚Ì‚à‚Ì‚ª‚ ‚éB

1j‰ß胈[ƒh“Š—^EÛŽæ‚É ‚æ‚ébó‘B‹@”\’á‰ºÇ‚Í ƒˆ[ƒh§ŒÀ‚ʼnñ•œ

@‰ß胈[ƒhÛŽæ‚É‚æ‚èbó ‘B‹@”\’ቺǂɂȂ邱‚Æ‚ª‚  ‚éi}2jBƒˆ[ƒh§ŒÀ‚É‚æ ‚èbó‘B‹@”\’ቺǂ©‚ç‰ñ•œ ‚·‚éBƒˆ[ƒh‘¢‰eÜ‚É‚æ‚èb ó‘B‹@”\’ቺǂɂȂé—Ⴊ‚  ‚éBAmiodarone‚Í1 ùi100mgj‚É37.3mg‚̃ˆ[ƒh‚ðŠÜ‚ÞB Amiodarone ‚Íbó‘B‹@”\’ቺǂ̌´ˆö‚É‚È ‚éBŠî‘b‚É‹´–{•a‚ª‚ ‚éB

}2

}2D‹´–{•a‚ÌŠ³ŽÒ‚Ńˆ[ƒh‘¢‰eÜ‚É‚æ‚èbó‘B‹@”\’ቺǂɂȂÁ‚½—á
75Η«Bbó‘B‹@”\³í‚Ì‹´–{•a‚ÅŒo‰ß‚ðŠÏ‚Ä‚¢‚½B®Œ`ŠO‰È‚Ńˆ[ƒh‘¢‰eÜ ‚ðÃ’ŒãAbó‘B‹@”\’ቺǂɂȂÁ‚½B‚»‚ÌŒãbó‘B‹@”\’ቺǂ©‚ç‰ñ•œ‚µ‚½9jB

}3

}3. RifampiciniRFPj‚É‚æ‚ébó‘B‹@”\’ቺÇ11A12j
62 Ë’j«B”xŒ‹ŠjŽ¡—ÂÉRifampicin ‚ð“Š—^‚µ‚½BTSH 170 mU/l ‚É‚È‚Á‚½B
bó‘B‹@”\’ቺǂɂȂÁ‚½BT4 ‚ð“Š—^‚µ‚½B
T3 F Triiodothyronine; T4 F Thyroxine; TSH F Thyroid-stimulating hormone

2j–òÜ‚É‚æ‚ébó‘B‹@”\’ቺÇ

@Rifampicin ‚Íbó‘B‹@”\’ቺǂð—U”­‚·‚é i}3j11,12jB–«bó‘B‰Ši‹´–{•aj‚ÌŠ³ŽÒ‚ÉRŒ‹ŠjÜRifampicin ‚ð“Š—^‚·‚é‚ÆA bó‘B‹@”\’ቺǂɂȂ邱‚Æ‚ª‚ ‚éB Rifampicin‚ÍŠÌ‘Ÿ‚Å‚Ìbó‘Bƒzƒ‹ƒ‚ƒ“ ‘ãŽÓ‚ð‘£i‚·‚éBbó‘Bƒzƒ‹ƒ‚ƒ“‚Ì‘ãŽÓ ‚ª‘£i‚³‚êAbó‘B‹@”\’ቺǂɂȂéB Rifampicin“Š—^’†‚ÍT4‚ð“Š—^‚·‚éBb ó‘B‹@”\’ቺǂð—U”­‚·‚é–òÜ‚Í‘½‚¢ i•\3jB

•\3Dbó‘Bƒzƒ‹ƒ‚ƒ“‡¬E•ª”åA‘ãŽÓ‚ɉe‹¿‚ð‹y‚Ú‚µA bó‘B‹@”\’ቺǂ̌´ˆö‚É‚È‚é–òÜ

•\3

3j–³’É«bó‘B‰Š

@Ž©ŒÈ–Ɖu«bó‘B‰Š‚ňê‰ß«‚Ìbó‘B‘gD ”j‰ó‚𶂶Aˆê‰ß«bó‘B‹@”\’á‰ºÇ‚É‚È ‚éBŽYŒã‚ƃNƒbƒVƒ“ƒOpŒãbó‘B‹@”\’á‰ºÇ ‚Í‚±‚Ì“ÁŽêŒ^B

4jŽYŒãˆê‰ß«bó‘B‹@”\’ቺÇ

@ŽYŒãbó‘B‹@”\ˆÙíÇ‚ª‚ ‚éBŽYŒãˆê‰ß« bó‘B‹@”\’ቺǂª‚ ‚éB–«bó‘B‰Ši‹´ –{•aj‚Å‚ ‚éBŽYŒãbó‘B‹@”\ˆÙíÇ‚Ì’†‚Å ‚àŽYŒãˆê‰ß«bó‘B‹@”\’ቺǂ͕p“x‚ª‘½ ‚¢B”DP‚É‚æ‚èˆêŽž“I‚ɃXƒeƒƒCƒh‰ßè‚É‚È ‚èA•ª•Ø‚É‚æ‚èƒXƒeƒƒCƒh‰ßè‚©‚ç‰ð•ú‚³ ‚êA–ƉuˆÙ킪‹N‚±‚éBŽYŒãbó‘B‹@”\ˆÙí Ç‚Ì”­Ç‹@˜‚ðŽŸ‚ÉŽ¦‚·ƒNƒbƒVƒ“ƒOpŒãbó ‘B‹@”\ˆÙíÇ‚Íà–¾‚·‚éB

5jƒNƒbƒVƒ“ƒOpŒãˆê‰ß«bó‘B‹@”\’ቺÇ

@ƒNƒbƒVƒ“ƒOpŒãbó‘B‹@”\ˆÙíÇ‚ª‚ ‚é13,14jB ƒNƒbƒVƒ“ƒOpŒã‚Ɉê‰ß«‚ ‚é‚¢‚͉i‘±«‚Ìb ó‘B‹@”\’ቺǂɂȂé‚à‚Ì‚ª‚ ‚éi}4jBƒNƒbƒVƒ“ƒO‚ŃXƒeƒƒCƒh‰ßè‚É‚È ‚èA–Ɖu”½‰ž‚ª—}§‚³‚êA‚»‚µ ‚ÄŽèp‚É‚æ‚èƒXƒeƒƒCƒh‰ßè‚© ‚ç‰ð•ú‚³‚ê‚é‚ÆA–ƉuˆÙ킪‹N ‚±‚éB

}4

}4DƒNƒbƒVƒ“ƒOpŒãˆê‰ß«bó‘B‹@”\’ቺÇ13,14j
27΂ÌCarney's complex‚Ì’j«B‰¡Ž²0‚̓NƒbƒVƒ“ƒOÇ ŒóŒQ‚ɑ΂·‚éŽèp‚Åbilateral adrenalectomy‚ð‚µ‚½Žž‚ð•\ ‚í‚·BX‚Í•›t”玿ƒzƒ‹ƒ‚ƒ“‚ð“Š—^’†‚Å‚ ‚邱‚Æ‚ðŽ¦‚·B
MHA Fƒ}ƒCƒNƒƒ][ƒ€R‘ÌiTPOAbjATAFƒTƒCƒƒOƒ ƒuƒŠƒ“R‘ÌiTGAbj

6jƒuƒƒbƒLƒ“ƒOR‘ÌiTSBAbj ÁŽ¸‚É”º‚¤‰Â‹t«bó‘B‹@”\ ’ቺÇ8j

@ƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb Á Ž¸‚É”º‚¢bó‘B‹@”\’ቺǂ©‚ç ‰ñ•œ‚·‚éǗႪ‚ ‚éi}5j

7jŒ´ˆö•s–¾‚̉‹t«bó‘B‹@ ”\’ቺÇ

@Œ´ˆö•s–¾‚̉‹t«bó‘B‹@”\ ’ቺǂ͑½‚¢10jBbó‘Bƒzƒ‹ƒ‚ ƒ“•ž—p’†‚Ì–«bó‘B‰Š‚É‚æ‚é bó‘B‹@”\’ቺNJ³ŽÒ‚Ì1/5 ‚Í bó‘Bƒzƒ‹ƒ‚ƒ“‚𒆎~‚·‚邱‚Æ ‚ª‚Å‚«‚éB5l‚É1l‚Íbó‘Bƒz ƒ‹ƒ‚ƒ“‚ð•s•K—v‚É“Š—^‚³‚ê‚Ä‚¢ ‚éBbó‘Bƒzƒ‹ƒ‚ƒ““Š—^‚ÍS‹Ø [ÇA‹·SÇAŽž‚É‚Íœ‘eé Ç ‚ðˆø‚«‹N‚±‚·‚±‚Æ‚ª‚ ‚éB

}5

}5DƒuƒƒbƒLƒ“ƒOR‘ÌÁŽ¸‚É”º‚¤‰Â‹t«bó‘B‹@”\’ቺÇ8j
ƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb —z«‚ÌŽ©ŒÈ–Ɖu‚É‚æ‚ébó‘B‹@”\’ቺŠ³ŽÒ21 —á ‚Ì10 ”N‚ɂ킽‚éŠÏŽ@B21 —á’†AÇ—á1 ` 15i‡TAA‡TBj‚Ì15 —á‚ÅTSBAb i‚±‚±‚Å‚ÍTBIIj‚ÍÁŽ¸‚µ‚½‚ªAÇ—á16 ` 21 ‚Ì6 —á‚Å‚ÍTBII ‚Í‚’l‚Ì‚Ü‚Ü ‚Å‚ ‚Á‚½BÇ—á1 ` 6i‡T Aj‚ÍTBII ÁŽ¸‚É”º‚¢Abó‘B‹@”\’ቺǂ©‚ç‰ñ •œ‚µ‚½B‰Â‹t«bó‘B‹@”\’ቺǂł ‚Á‚½BÇ—á7 ` 21i‡T BA‡Uj‚Íb ó‘B‹@”\’ቺǂ̂܂܂ł ‚Á‚½B‡U‚͈Þk«bó‘B‰Š‚Åbó‘B‹@”\’á‰ºÇ ‚Ì‚Ü‚Ü‚Å‚ ‚éBTBII, TSBAb ‚Íí‚É—z«B
TBII FTSH binding inhibitory IgG, TSBAbFTSH-stimulation blocking Ab.
œFbó‘BŽîi{jA›Fbó‘BŽîi|jB

4j‹´–{•abó‘B‹@”\’ቺǂ©‚ç ƒoƒZƒhƒE•abó‘B‹@”\˜´iÇ‚ÉA ‚»‚µ‚Ävice versa2,15,16j

ŽhŒƒR‘ÌTSAb ‚©‚çƒuƒƒbƒLƒ“ ƒOR‘ÌTSBAbA‹t‚ÉTSBAb ‚©‚ç TSAb ‚É‚È‚éǗႪ‚ ‚é2jBTRAb ‚É‚ÍŽhŒƒR‘ÌTSAb ‚ƃuƒƒbƒLƒ“ ƒOR‘ÌTSBAb ‚ª‚ ‚éBTBII ‚Í TSAb ‚ÆTSBAb ‚ð‹æ•Ê‚µ‚È‚¢B TSAb ‚ÆTSBAb ‚Í‚Æ‚à‚ÉTSH Žó —e‘ÌR‘ÌTRAb ‚Å‚ ‚éBTSBAb ‚©‚çTSAb ‚É‘ã‚í‚éǗႪ‚ ‚é i}6jBTSBAb ‚É‚æ‚ébó‘B‹@”\ ’ቺǂ©‚çAŽhŒƒR‘ÌTSAb ‚É‚æ ‚éƒoƒZƒhƒE•a‚É‚È‚é—Ⴊ‚ ‚éB‹t ‚ÉTSAb ‚©‚çTSBAb ‚É‚È‚éÇ—á ‚ª‚ ‚éB

ƒoƒZƒhƒE•a‚Æ‹´–{•a‚Íbó‘B‹@”\˜´iÇ‚Æb ó‘B‹@”\’ቺǂƕ\Œ»‚Í‹t‚Å‚ ‚邪A“¯ˆêŒÂl ‚»‚µ‚ĉƑ°“à‚É”­Ç‚·‚éBƒoƒZƒhƒE•a‚Æ‹´–{•a‚Í “¯ˆê‚̈â“`‚Ɗ‹«‚ð”wŒi‚É”­Ç‚·‚éB‚ǂ̂悤‚È ‹@˜‚ŃoƒZƒhƒE•abó‘B‹@”\˜´iÇ‚ ‚é‚¢‚Í‹´–{ •abó‘B‹@”\’ቺǂɂȂ邩‚Í•s–¾‚Å‚ ‚éB

}6

}6DƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚É‚æ‚ébó‘B‹@”\’ቺǂ©‚çTSAb ‚É‚æ‚éƒoƒZƒhƒE •a‚É‚È‚Á‚½—á2j
44 Η«BƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚É‚æ‚ébó‘B‹@”\’ቺǂ©‚çTSAb ‚É ‚æ‚éƒoƒZƒhƒE•a‚É‚È‚Á‚½B
TSBAb F TSH-stimulationblocking Ab, TSAb F
thyroid stimulating Ab, TBII F TSH binding inhibitory immunoglobulin,
MMI F 1-methyl-2-mercapto-imidazoleiƒƒ‹ƒJƒ][ƒ‹j, T4 F thyroxine.

‡]. ‚¨‚í‚è‚É

‹´–{•a‚Ìf’f‚Í‘gDf‚Å‚ ‚é1jB‚µ‚©‚µA‘S ‚Ä‚ÌÇ—á‚Å‘gD‚ð‚݂邱‚Æ‚Í‚Å‚«‚È‚¢B TPOAbATGAb ‚ª—z«‚ÅAbó‘B‹@”\’á‰ºÇ ‚ª‚ ‚é‚Æ‚«A‹´–{•a‚É‚æ‚ébó‘B‹@”\’ቺǂð l‚¦‚éBTPOAbATGAb‚̓oƒZƒhƒE•a‚Ì TRAb iTBII ETSAbj‚Ù‚ÇŠ´“xE“ÁˆÙ“x‚ª —Ç‚­‚Í‚È‚­A‹´–{•a‚ÌŽw•W‚É‚·‚¬‚È‚¢B

‚Ü‚½ƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚Íbó‘B‹@”\ ’ቺǂ̌´ˆö‚Å‚ ‚é5,7,8,16jBTSBAb ‚͈Þk«b ó‘B‰Š‚ÌŒ´ˆö‚Å‚ ‚éB

•¶@Œ£
1jHashimoto H. Zur Kenntniss der lymphomatosen Veranderung der Schilddruseistruma lymphomatosaj. Arch Klin Chir 97 F 219-248, 1912
2jTakasu N, et al. Hashimotofs thyroiditis F TGAb, TPOAb, TRAb and recovery from hypothyroidism. Expert Review of Clinical Immunology 4 F 221-237, 2008
3j‚{Ms@–«bó‘B‰Ši‹´–{•aj‘Ž‡—Õ°@49 F 2199-2204, 2000
4jAkamine H, Takasu N, et al. Association of HTLV-I with autoimmune thyroiditis in patients with adult Tcell leukaemia iATLj and in HTLV-I carriers. Clin Endocrinol iOxfj 45 F 461-466, 1996
5jTakasu N, et al. Evidence for thyrotropin iTSHj- blocking activity in goitrous Hashimoto's thyroiditis with assays measuring inhibition of TSH receptor binding and TSH-stimulated thyroid adenosine 3',5'- monophosphate responses/cell growth by immunoglobulins. J Clin Endocrinol Metab 64 : 239- 245, 1987
6j‚{Ms@bó‘B‹@”\’ቺÇ@‘Ž‡—Õ°56 F 1587-1596, 2007
7jTakasu N, et al.F Transient neonatal hypothyroidism due to maternal immunoglobulins that inhibit thyrotropin-binding and post-receptor processes. J Clin Endocrinol Metab 59 F 142-146, 1984
8jTakasu N, et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 326 F 513- 518, 1992
9j‚{Ms@‹´–{•a; bó‘B‹@”\’ቺǂÌf’f‚ÆŽ¡—ÃA ‚»‚µ‚ĉ‹t«bó‘B‹@”\’ቺÇ. “ú–{“à‰ÈŠw‰ïŽGŽ 86 F 1147-1155, 1997
10jTakasu N, et al. Test for recovery from hypothyroidism during thyroxine therapy in Hashimoto's thyroiditis. Lancet 336i8723jF 1084-1086, 1990
11jTakasu N, et al. Rifampin-induced hypothyroidism in patients with Hashimoto's thyroiditis. N Engl J Med 352 F 518-519, 2005
12jTakasu N, et al. Rifampin-induced hypothyroidism. J Endocrinol Invest 29 F 645-649, 2006
13jTakasu N, et al. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma. N Engl J Med 322 F 1708-1712, 1990
14jTakasu N, et al. Development of autoimmune thyroid dysfunction after bilateral adrenalectomy in a patient with Carney's complex and after removal of ACTHproducing pituitary adenoma in a patient with Cushing's disease. J Endocrinol Invest 16 F 697-702, 1993
15jTakasu N, et al. Graves' disease following hypothyroidism due to Hashimoto's disease F studies of eight cases. Clin Endocrinol iOxfj 33 F 687-98, 1990
16jTakasu N, et al. TSBAb iTSH-stimulation blocking antibodyj and TSAb ithyroid stimulating antibodyj in TSBAb-positive patients with hypothyroidism and Graves' patients with hyperthyroidism. Horm Metab Res 33 F 232-337, 2001

ƒL[ƒ[ƒh
bó‘BŽ©ŒÈ–ƉuŽ¾Š³AƒoƒZƒhƒE•aA‹´–{•aA–«bó ‘B‰ŠAbó‘B‹@”\’ቺÇAbó‘Bƒzƒ‹ƒ‚ƒ“A‰Â‹t«b ó‘B‹@”\’ቺÇAˆê‰ß«bó‘B‹@”\’ቺÇATSH Žó —e‘ÌR‘Ìi T R A b jAbó‘BƒuƒƒbƒLƒ“ƒOR‘Ì iTSBAbjAbó‘BŽhŒƒR‘ÌiTSAbjAƒˆ[ƒhAƒŠƒt ƒ@ƒ“ƒsƒVƒ“AƒNƒbƒVƒ“ƒOÇŒóŒQ



’˜@ŽÒ@Ð@‰î

ûü{Ms

—®‹…‘åŠwˆãŠw•”@‘æ“ñ“à‰È‹³Žö
ûü{@Ms

og’nFˆ¤’mŒ§

og‘åŠwF“Œ‹žˆã‰ÈŽ•‰È‘åŠw

—ª—ð
Œ»Ý@—®‹…‘åŠwˆãŠw•”@‘æ“ñ“à‰È‹³Žö
“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘²‹ÆAƒtƒ‰ƒ“ƒX‘—§‰q¶Œ¤‹†Š
Œ¤‹†Žå”CAMB‘åŠwˆãŠw•”•‹³Žö

êUEf—×̈æ
@bó‘BE“à•ª”åE“œ”A•aE‘ãŽÓ

‚»‚Ì‘¼EŽï–¡“™
@ŽR“o‚èA…‰jA“Ç‘AŽG•¶‚ð‘‚­‚±‚ÆB



Q U E S T I O N I

–â‘èFˆÈ‰º‚Ì‹Lq‚ų‚µ‚¢‚Ì‚Í‚Ç‚ê‚©BŽO‚ ‘I‚×B

  • aDTSH Žó—e‘ÌR‘ÌTRAb ‚É‚Íbó‘BŽhŒƒR‘Ì TSAb ‚ƃuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚ª‚ ‚éB
  • bDbó‘BŽhŒƒR‘ÌTSAb ‚̓oƒZƒhƒE•a‚ÌŒ´ˆö ‚Å‚ ‚éB
  • cDƒuƒƒbƒLƒ“ƒOR‘ÌTSBAb ‚Íbó‘B‹@”\’á ‰ºÇ‚ÌŒ´ˆö‚Å‚ ‚éB
  • dD‹´–{•a‚ÌŠ³ŽÒ‚Í‚·‚ׂÄbó‘B‹@”\’ቺǂŠ‚ ‚éB
  • eDbó‘B‹@”\’ቺǂ̊³ŽÒ‚É‚Í‚·‚ׂÄbó‘BŽî ‚ª‚ ‚éB

CORRECT ANSWER!@4ŒŽ†ivol.44j‚̳‰ð

• o‹¾i•â•j‰º‚ÌŠÌØœp‚¨‚æ‚у‰ƒW ƒI”gÄŽÜp

–â‘èF• o‹¾i•â•j‰ºŠÌØœp‚ÉŠÖ‚·‚鎟‚Ì ‹Lq‚Ì’†‚©‚糂µ‚¢‚à‚Ì‚ð‘I‘ð‚¹‚æB

  • ‹C• ‚É‚æ‚é‚à‚Á‚Æ‚àŠëŒ¯‚ȇ•¹Ç‚ÍpŒão ŒŒ‚Å‚ ‚éB
  • ¶—tŠO‘¤‹æˆæØœ‚Í“K‰ž‚Æ‚È‚ç‚È‚¢B
  • ŽèpŽžŠÔ‚Ì’Zk‚ÉvŒ£‚µ‚¤‚éB
  • pŒã”x‰Š’ጸ‚ÌŒø‰Ê‚ÍŠú‘Ò‚Å‚«‚È‚¢B
  • ŠÌ‰E—tŒã‹æˆæ‚ÌŽèp‚ÍŽ{s‚Å‚«‚È‚¢B

³‰ð@3